CSIMarket Company Name, Ticker, Suppliers, else..


Idexx Laboratories Inc  (NASDAQ: IDXX)
Other Ticker:  
 

Idexx Laboratories Inc

IDXX's Fundamental analysis



Looking into Idexx Laboratories Inc growth rates, revenue grew by 6.56 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 496

In Vitro & In Vivo Diagnostic Substances industry recorded growth of revenues by 5.91 %

Idexx Laboratories Inc's net income grew by 9.71 % in III. Quarter 2024 year on year, above company average,

• More on IDXX's Growth


Idexx Laboratories Inc
current PE on trailing twelve month basis is below In Vitro & In Vivo Diagnostic Substances industry average.

Idexx Laboratories Inc PEG ratio is at 7.6 Idexx Laboratories Inc realized cash reduction of $ -0.28 per share in trailing twelve-month period.
In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months.
Company
41.98
PE TTM   
Industry
419.13
PE TTM    
Company's Price to Sales ratio is at 9.41.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 8.85.


• More on IDXX's Valuation
 
 Total Debt (Millions $) 624
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 349,403
 Net Income/Employee (TTM) $ 78,749
 Receivable Turnover (TTM) 7.65
 Tangible Book Value (Per Share $) 13.23

Idexx Laboratories Inc
current PE on trailing twelve month basis is below In Vitro & In Vivo Diagnostic Substances industry average.

Idexx Laboratories Inc PEG ratio is at 7.6 Idexx Laboratories Inc realized cash outflow of $ -0.28per share in trailing twelve-month period.
In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months.
Company
41.98
PE TTM   
Industry
419.13
PE TTM    
Company's Price to Sales ratio is at 9.41.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 8.85.

Idexx Laboratories Inc Price to Book Ratio is at 22.35 lower than Industry Avg. of 373.14. and higher than S&P 500 Avg. of 0.01

• More on IDXX's Valuation

•  Market Capitalization (Millions $) 36,157
•  Shares Outstanding (Millions) 83
•  Employees 11,000
•  Revenues (TTM) (Millions $) 3,843
•  Net Income (TTM) (Millions $) 866
•  Cash Flow (TTM) (Millions $) -23
•  Capital Exp. (TTM) (Millions $) -124
•  Total Debt (Millions $) 624
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 349,403
•  Net Income/Employee(TTM) $ 78,749
•  Receivable Turnover Ratio (TTM) 7.65
•  Tangible Book Value (Per Share $) 13.23

•  Market Capitalization (Millions $) 36,157
•  Shares Outstanding (Millions) 83
•  Employees 11,000
•  Revenues (TTM) (Millions $) 3,843
•  Net Income (TTM) (Millions $) 866
•  Cash Flow (TTM) (Millions $) -23
•  Capital Exp. (TTM) (Millions $) -124


    IDXX's Profitability Comparisons
Idexx Laboratories Inc achieved increase in profitability, due to cost control. Operating Margin grew in III. Quarter 2024 to 31.17 % from 26.3 % in II. Quarter.

Idexx Laboratories Inc net profit margin of 23.88 % is currently ranking no. 2 in In Vitro & In Vivo Diagnostic Substances industry, ranking no. 43 in Healthcare sector and number 562 in S&P 500.


Profitability by Segment
CAG 31.06 %
Water 47.06 %
LPD 3.07 %
Other 52.58 %
Total 23.88 %



  Ratio
•   Capital Ratio (MRQ) 1.42
•  Total Debt to Equity (MRQ) 0.39
•  Tangible Leverage Ratio (MRQ) 1.58
•  Asset Turnover Ratio (TTM) 1.19
•  Inventory Turnover Ratio (TTM) 3.92



Idexx Laboratories Inc achieved increase in profitability, due to cost control. Operating Margin grew in III. Quarter 2024 to 31.17 % from 26.3 % in II. Quarter.

Idexx Laboratories Inc net profit margin of 23.88 % is currently ranking no. 2 in In Vitro & In Vivo Diagnostic Substances industry, ranking no. 43 in Healthcare sector and number 562 in S&P 500.

• More on IDXX's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com